IONS (Ionis Pharmaceuticals, Inc. Common Stock) Stock Analysis - SEC Filings

Ionis Pharmaceuticals, Inc. Common Stock (IONS) is a publicly traded Healthcare sector company. As of May 21, 2026, IONS trades at $75.44 with a market cap of $11.98B and a P/E ratio of 74.97. IONS moved +1.63% today. Year to date, IONS is -4.42%; over the trailing twelve months it is +117.75%. Its 52-week range spans $23.95 to $86.74. Analyst consensus is strong buy with an average price target of $105.94. Rallies surfaces IONS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find IONS SEC filings?

Rallies organizes IONS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

IONS Key Metrics

Key financial metrics for IONS
MetricValue
Price$75.44
Market Cap$11.98B
P/E Ratio74.97
EPS$1.00
Dividend Yield0.00%
52-Week High$86.74
52-Week Low$23.95
Volume473
Avg Volume0
Revenue (TTM)$1.06B
Net Income$154.57M
Gross Margin98.35%

Latest IONS News

Recent IONS Insider Trades

  • Monia Brett P sold 3.22K (~$253.35K) on May 14, 2026.
  • Monia Brett P sold 1.32K (~$102.67K) on May 13, 2026.
  • LOSCALZO JOSEPH sold 59.51K (~$4.46M) on May 4, 2026.

IONS Analyst Consensus

17 analysts cover IONS: 0 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $105.94.

Common questions about IONS

Where can I find IONS SEC filings?
Rallies organizes IONS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show IONS 10-K and 10-Q filings?
Rallies organizes IONS SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is IONS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IONS. It does not provide personalized investment advice.
IONS

IONS